• AAPL 169.89
  • TSLA 170.18
  • AMZN 173.67
  • MSFT 399.04
  • INTC 35.11
  • EURUSD 1.0728
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NASDAQ /
  3. GNFT.NASDAQ

Genfit (GNFT NASDAQ) stock market data APIs

$3.42 -0.03(-0.9%) as of April 25, 2024

Genfit Financial Data Overview

3.45
3.42
-
3.5586
3.4
2.894-4.75
174 M
49 861 K
34 483 K
0
0.867
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'GNFT',
Type: 'Common Stock',
Name: 'Genfit',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
ISIN: NULL,
CUSIP: NULL,
CIK: NULL,
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: '2019-03-27',
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: 'ADR',
IsDelisted: false,
}

Genfit Fundamental Data is available in our Financial Data APIs

  • Net Revenue 34 483 K
  • EBITDA -29 268 000
  • Earnings Per Share -0.62
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Genfit Earnings via APIs

  • Latest Release 2024-04-04
  • EPS/Forecast 0

Get Genfit End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Genfit latest news via APIs

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

GENFIT S.A. Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland)July12, 2023– GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to impro...

Ipsen, Genfit's Elafibranor Shows Promise In Primary Biliary Cholangitis Patients

Ipsen SA (OTC: IPSEY) and Genfit SA (NASDAQ: GNFT) announced topline data from the Phase 3 ELATIVE trial evaluating the efficacy and safety of elafibranor for primary biliary cholangitis (PBC) who hav...
Do you have any questions?
support@eodhistoricaldata.com